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Abstract
Background:  Uncertainties surrounding the effectiveness and cost-effectiveness of childhood tonsillectomy for
recurrent sore throat led the NHS Health Technology Assessment Programme to commission this research to evaluate
the effectiveness and cost-effectiveness of tonsillectomy and adeno-tonsillectomy in comparison with standard non-
surgical management in children aged under 16 with recurrent throat infections. The aim is to evaluate if tonsillectomy
and adeno-tonsillectomy reduces the number of episodes of sore throats among children to a clinically significant extent.
Methods/design: A simple prospective pragmatic randomised controlled trial with economic analysis and prospective
cohort study of non-trial participants comparing surgical intervention with conventional medical treatment. The
treatment arm will receive tonsillectomy and adeno-tonsillectomy while in the control arm non-surgical conventional
medical treatment only will be used. The primary outcome measure will be reported number of episodes of sore throat
over two years with secondary outcomes measures of reported number of episodes of sore throat, otitis media and
upper respiratory tract infection which invoke a GP consultation; reported number of symptom-free days; reported
severity of sore throats and surgical and anaesthetic morbidity. The study will take place in five hospitals in the UK. The
trial population will be 406 children aged 4–15 on their last birthday with recurrent sore throat referred by primary care
to the 5 otolaryngology departments. The duration of the study is seven years (July 2001- July 2008).
Discussion: As with all pragmatic randomised controlled trials it is impossible to control the external environment in
which the research is taking place. Since this trial began a number of factors have arisen which could affect the outcome
including; a reduction in the incidence of respiratory tract infections, marked socio-economic differences in consultation
rates, the results from the National Prospective Tonsillectomy Audit and the Government's waiting list initiatives.
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Background
In the UK sore throats cost the NHS an estimated £60 mil-
lion in GP consultations alone, result in 90,000 tonsillec-
tomy procedures, approximately half of which are in
children, and a loss of more than 35 million school or
work days annually[1]. The incidence of tonsillectomy
has risen since the early 1990's, although levels are still
much lower than in the 1930's, when 100,000 operations
were performed in UK school children[2]. Adenoidec-
tomy is performed with tonsillectomy in about one third
of patients. Private medical insurance is associated with
higher selective ENT surgical rates under the age of seven
years[3] and 16% of UK ENT activity is in the independent
sector. Therefore figures based purely on NHS returns
inevitably underestimate the total activity. In addition to
the health care costs, tonsillectomy incurs parental costs
as one parent usually resides in hospital overnight. There-
after the average time to return to normal activity for
under 15 year olds is 12 days[4].
There is a broad similarity in the criteria for tonsillectomy
in clinical guidelines in the UK [5,6] and North Amer-
ica[7]. The minimum criteria are typically a two year his-
tory of three to four sore throats of moderate severity (five
day duration) per annum. This is despite evidence that
even histories that seem impressive may not be confirmed
on close scrutiny in the majority[8]. The complex psycho-
social influences on tonsillectomy rates include parental
enthusiasm for intervention[9], lack of information[10]
and maternal use of psychotropic drugs which increases
two-fold the rate of consultation for childhood sore throat
[11,12]. Guidelines may not be uniformly implemented,
even when locally derived. Surgeons tend to break guide-
lines more often in favour of performing than withhold-
ing surgery[5].
National and international variations in the rates of
adeno-tonsillectomy have been recognised for decades.
Even in the 1930's, 50% of UK and USA children received
a tonsillectomy, while the rate was 0.5% or lower in Ger-
many[2]. A survey of such variation in Quebec, high-
lighted the importance of clinical uncertainty among
physicians about the recommendation of surgical inter-
vention[13], providing further support for conducting pri-
mary research. The Scottish National Tonsil Audit showed
that rates of tonsillectomy in childhood varied from <4/
10,000 in Forth Valley to almost 10/10,000 in Dumfries
and Galloway[14].
Differential costs and benefits of surgery at different age
groups are not known. The tonsils are traditionally
thought to undergo a period of physiological enlargement
around school entry. At this time also, pathological seque-
lae may include otitis media. Older children and adoles-
cents, may have a somewhat different natural history, and
illness at this age has rather different (educational) impli-
cations.
Mortality from tonsillectomy has been estimated at 1/
16000 to 1/35000[15], but surgical risk at this level is
hard to measure, to conceptualise and to convey. The
major nonfatal complications are infection, haemorrhage
(2.15%), and pain which lasts on average five to six days
[16,17] and may be inadequately treated in children[18].
Haemorrhage is unpleasant, requires intravenous fluid
administration, with or without blood transfusion and
return to theatre. The reported rate of second anaesthetic
for haemostasis varies widely from 0.75% in one British
review[4], to as low as 0.06% in a study of almost 9409
children in Toronto[19]. The post tonsillectomy readmis-
sion rate is up to 7%[4], but in Newcastle in childhood is
only 2.3% (unpublished data; Department of Clinical
Effectiveness, Freeman Hospital, Newcastle). The overall
reported complication rate ranges from 8%[14] to
14%[17], the majority being relatively minor such as sore
throat, nausea, fever, dysphagia. Most two to 10 year olds
undergoing ENT surgery show behavioural changes such
as attention seeking, temper tantrums and night waking
and there is also anecdotal evidence for depression after
tonsillectomy[20]. Younger children, due to cognitive
immaturity seem less well able to adapt to hospitalisation
[21,22]. Late sequelae may include lower postoperative
serum immunoglobulin levels but these have been
ascribed to reduction in antigen stimulation[23]. There is
continuing debate about the suggestion that tonsillec-
tomy increases the risk of Hodgkin's lymphoma[24]. A
substantial Scandinavian population based cohort study
found an increased risk of Hodgkin's disease, especially in
younger children[25]. The risk of transmission of nvCJD
from contaminated tonsillectomy instruments remains
quite unquantified. Some centres are costing the use of
disposable tonsillectomy sets.
Despite the frequency of tonsil dissection, there is a
remarkable lack of robust evidence for its efficacy. Uncon-
trolled patient reports suggest the procedure to be very
effective but recurrent sore throat, particularly in child-
hood may be a self limiting disease. Where non-interven-
tion control groups have been studied, the benefits of
tonsillectomy seem almost to disappear after two years.
Available studies are either 20 to 30 years old or confined
to small numbers of severely affected individuals with
limited general applicability. The most recently published
Cochrane review concludes that there is no evidence from
randomised controlled trials to guide the clinicians in for-
mulating the indications for surgery in children or
adults[26]. The authors state the need for high quality evi-
dence from randomised controlled trials to establish its
effectiveness and that these should assess the effectiveness
of the procedure in patients with throat infections of dif-BMC Ear, Nose and Throat Disorders 2006, 6:13 http://www.biomedcentral.com/1472-6815/6/13
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fering severity and frequency. A recent Dutch randomised
controlled trial of adenotonsillectomy versus watchful
waiting reported no differences between treatment arms
for children with mild symptoms and only a small differ-
ence of less than one episode of fever a year between treat-
ment arms for children with moderate symptoms[27].
The Scottish National Tonsillectomy Audit[14] showed
high levels of patient satisfaction and that 80% of subjects
did not consult a doctor in the subsequent 12 months.
However, over the past 30 years a number of controlled
studies with longer follow-up indicate marginal and
diminishing levels of clinical benefit over a period of non-
intervention. There are no substantial claims for the ben-
efit of childhood tonsillectomy after 2 years. Roos[28]
assessed the benefit to be 1 to 1.5 fewer sore throats (0.5
to 1 episode per annum) over the first two years after sur-
gery in those with three to four episodes per annum pre-
operatively. Other studies [29-31] showed benefits of the
order of ~1.5 fewer sore throats versus controls in the first
postoperative year and on average one fewer episode in
the second year. All of these and other available studies
provide inadequate evidence because of poor definition
of entry and outcome criteria, failure to include intention
to treat calculations and small or skewed samples[32].
Even the only scientifically acceptable study by Paradise
and colleagues[17] suffered from comparatively small
numbers of a skewed population of more severely affected
children. The benefits of surgery were more marked
(approximately 1.75 fewer episodes in year 1, 1.5 in year
2) but equally short lived. The drop out rate was 34% by
the end of year 2 and 1 in 3 of the control group under-
went surgery and were excluded from analysis. Also, the
very active therapy of the control arm may have mitigated
any impact of surgery. The Paradise group went on to
study a more typical i.e. less severely affected group of
children, but the full results of this study, near completion
in 1992 have never been reported.
Weight gain is a cited supplementary benefit of tonsillec-
tomy. Two recent studies showed accelerated weight gain
postoperatively, but as the children were shown to be of
normal or above average height and weight preopera-
tively, this effect may be undesirable[33]. There appears so
far to be only minimal additional benefit from adenoid-
ectomy or adenotonsillectomy in recurrent acute otitis
media [16].
A straw poll, for this protocol, of consultant otolaryngol-
ogists asked: what level of reduction in sore throat would
justify removal of the tonsils? Replies were remarkably
consistent – at least 2 sore throats fewer per annum. No
published trial to date shows a benefit of this magnitude,
even in the first year after surgery. There is a pressing need
for a UK, pragmatic trial to evaluate the effectiveness and
cost-effectiveness of childhood tonsillectomy.
The purpose of this study therefore is to answer the key
research question "What is the effectiveness and cost-
effectiveness of tonsillectomy/adeno-tonsillectomy in
comparison with standard non-surgical management in
children aged under 16 with recurrent throat infections?"
Assessment of outcome will emphasise those which are
important to children themselves and their parents or car-
ers. Specific research questions are;
￿ Does tonsillectomy/adeno-tonsillectomy reduce the
number of episodes of recurrent sore throats among chil-
dren to a clinically significant extent?
￿ Are there differences in clinical outcome for the age
groups: 4–7, 8–11, 12–15 years?
￿ What is the cost effectiveness of tonsillectomy/adeno-
tonsillectomy among children and what are the costs and
benefits to families?
￿ What are the important outcomes of tonsillectomy/
adeno-tonsillectomy for children and their parents/carers
and what is the importance of these to children and their
parents' quality of life?
￿ What are parents' (and older children's) preferences for
different treatment options for recurrent sore throat?




A simple prospective pragmatic randomised controlled
trial with economic analysis comparing surgical interven-
tion with conventional medical treatment.
Cohort design
We anticipate that a large majority of participants who
decline randomisation to the trial will opt for, and receive,
surgery. Therefore, in order to assess the external validity
of the trial results, we will recruit a cohort of children from
those who decline to participate in the trial. The cohort
will include both children who opt for surgery and those
who choose conventional medical treatment. They will be
followed up for 24 months.
Interventions
The treatment arm will receive tonsillectomy and adeno-
tonsillectomy while in the control arm non-surgical con-
ventional medical treatment only will be used.BMC Ear, Nose and Throat Disorders 2006, 6:13 http://www.biomedcentral.com/1472-6815/6/13
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Treatment
Tonsillectomy and adeno-tonsillectomy with adenoid
curettage and tonsillectomy by dissection or bipolar dia-
thermy. Most (80%) UK surgeons use the conventional
dissection method[4] and the remainder use bipolar dia-
thermy. Both methods will be allowed in the trial accord-
ing to surgical preference. Surgical intervention will take
place within four weeks of randomisation.
Control
Non-surgical conventional medical treatment only will be
used. There will be no active intervention protocol since
no single prescribing strategy would be able to cover all
patients[34]. The referring GP will be free to treat as in
their current practice. The use of usual treatment rather
than an active intervention protocol is considered impor-
tant for the implementation of study findings since surgi-
cal enthusiasts may argue against the findings were the
control group to be atypically and over rigorously treated.
Outcome measurement
The primary clinical outcome is the reported number of
episodes of sore throat in the two years after randomisa-
tion. Secondary clinical outcomes include reported
number of episodes of sore throat, otitis media and upper
respiratory tract infection which invoke a GP consulta-
tion; reported number of symptom-free days; reported
severity of sore throats and surgical and anaesthetic mor-
bidity. In addition to the measurement of these clinical
outcomes, the impact of the treatment on costs and qual-
ity of life will be assessed. There will also be an economic
evaluation.
Setting
Inpatient facilities and outpatient clinics of 5 hospitals in
the North of England and Scotland: Freeman Hospital,
Newcastle upon Tyne; Alder Hey Children's Hospital, Liv-
erpool; Booth Hall Children's Hospital, Manchester;
Yorkhill Royal Hospital for Sick Children, Glasgow; and
Bradford Royal Infirmary and general practices with
which study participants are registered. Freeman Hospital,
Newcastle is a large teaching hospital with a mixed adult
and paediatric ENT unit. The Unit has a wide urban and
rural catchment area including Newcastle and Gateshead,
Northumberland and north west Durham. Alder Hey
Hospital, Liverpool and Booth Hall Hospital, Manchester
house two of the largest paediatric ENT units in the UK
covering catchment areas in and around Liverpool and
Manchester. Yorkhill is a busy university hospital with the
largest children's ENT unit in Scotland and Bradford Royal
Infirmary is one of the major hospitals within West York-
shire. It has recently obtained teaching hospital status
with the opening of its medical school. The ENT unit acts
as a hub and supports clinics in Airedale and Dewsbury.
The unit supports the majority of adult and paediatric
care.
Target population
The trial population will be children aged 4–15 on their
last birthday with recurrent sore throat referred by pri-
mary care to 5 otolaryngology departments in Newcastle,
Liverpool, Manchester, Glasgow and Bradford. In 1999 a
total of 2683 tonsillectomy/adeno-tonsillectomy proce-
dures were done for children in these centres: Liverpool
(750), Manchester (440), Newcastle (545), Glasgow
(498) and Bradford (450) of which some two-thirds will
be referrals for recurrent sore throat.
Inclusion criteria
The study will use entry criteria drawn from the Northern
regional guidelines[5]. Children (or carers) reporting
experience of 4 or more episodes of sore throat within
each of 2 years or 6 or more episodes of sore throat within
1 year will be eligible. We have considered pre-randomi-
sation prospective data recording to operationalise stricter
inclusion criteria for severity, but have rejected these as
our aim is to operationalise current UK clinical practice.
Exclusion criteria
Children will be excluded if they require hospitalisation
due to quinsy; have obstructive symptoms suggestive of
clinically significant sleep apnoea syndrome, have rare
medical conditions such as glomerulonephritis or Hen-
och Schonlein purpura; have previously had a tonsillec-
tomy; have suspected velopharyngeal insufficiency, have
co-morbidity that means they are unable to undergo the
operation within the next 6 months, have a bleeding dis-
order, or have congenital/valvular heart disease.
Number of subjects required
We estimate a completed sample size at follow up of 284
children. Allowing for an attrition rate of around 30% we
will need to recruit a total of 406 children to the trial to
achieve the estimated sample of 284 (who will complete
the trial). Within the original three study hospitals some
1700 tonsillectomies/adeno-tonsillectomies are currently
performed annually. Only two thirds of these will have
recurrent sore throats. In any trial where the intervention
is widely used in current practice there are likely to be
large numbers of eligible participants who opt for the
intervention treatment and decline participation in the
trial. We estimate that this could be up to one half of all
eligible referrals from primary care. The maximum availa-
ble for randomisation is therefore estimated as 566 per
annum. Loss of eligible subjects in the trial is expected due
to holiday periods and 'winter pressures'. On the experi-
ence of loss in other trials (50%) a conservative estimate
would be 283 per annum. If we assume a conservative rate
of attrition of 30% over two years we would expect 198BMC Ear, Nose and Throat Disorders 2006, 6:13 http://www.biomedcentral.com/1472-6815/6/13
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completing trial participants to be recruited in a 12 month
period. Given seasonal effects a full 2 years would be nec-
essary to recruit the estimated sample size. The cohort
sample will be identified from participants who indicated
a preference not to be randomised within the trial and
who agreed to data collection. An appropriate sampling
fraction will be used once non-participation in the trial
can be estimated.
Subject recruitment
Recruitment to the study will take place in secondary care.
All GP referrals to study centres of children with recurrent
sore throat will be considered by participating surgeons.
Arrangements are in place in each centre for eligible chil-
dren to be referred to the clinical applicants. GPs will be
informed of this reorganisation. This will facilitate effi-
cient use of outpatients clinics at which trial participants
would be recruited. Trained Research Nurses will intro-
duce the trial to patients who will be shown a video
regarding the main aspects of the trial. Patients will also
receive information sheets. Research Nurses will discuss
the trial with patients in light of the information provided
in the video and information sheets. Patients will then be
able to have an informed discussion with the participating
consultant. Research Nurses will obtain written consent
from patients willing to participate in the trial. Informa-
tion sheets and consent forms are provided for all parents
involved in the trial however these have been amended
accordingly in order to provide separate information
sheets and consent form which are suitable for children
and teenagers. All information sheets, consent forms and
the video transcript have been translated into Bengali,
Punjabi, Gujarati, and Urdu. There are also separate infor-
mation sheets and consent forms for the cohort group.
Randomisation
Independent world wide web based computer randomisa-
tion will allocate participants to treatment arms. Ran-
domisation will take place once informed consent to the
study has been completed and baseline data collected.
The sample will be stratified by age of child at last birth-
day. Blocked randomisation will be used to ensure that
within each centre, within each of the three age groups (4–
7, 8–11, 12–15) children will be allocated in equal num-
bers to each arm of the trial. Where trial sites are unable to
access the world wide web they will telephone the coordi-
nating centre (University of Newcastle) in order for web
based randomisation to be completed on their behalf.
Sampling for the cohort study will similarly be stratified
by age.
Blinding
Health technology assessment is essentially a pragmatic
activity conducted in normal clinical practice, rather than
an exploratory activity conducted in highly controlled set-
tings. It follows that blinding doctors and patients to treat-
ment is not desirable since it distorts normal clinical
practice. Nor is it practicable. In contrast, blinding asses-
sors is important because it minimises subjective bias
towards a given treatment. All research staff conducting
interviews or processing postal questionnaires and diaries
will be blind to treatment modalities of all participants.
This will be facilitated by separating the responsibility for
recruitment and randomisation from outcome assess-
ment. Furthermore, participants will be encouraged to
respond to questions without describing their treatment
regime. In this way, we will minimise subjective bias
towards a given treatment.
Data collection and follow up
All participants will be followed up for 24 months from
the date of initial randomisation. To minimise recall bias,
data on sore throats will be gathered by a simple, struc-
tured daily health diary completed and returned by partic-
ipants on a monthly basis for 24 months. Experience of
similar studies suggests that with appropriate telephone
reminders 90% of diaries will be returned completed. In
addition simple outcome questionnaires, using two
postal reminders and a telephone reminder, will be sent
to trial and cohort study participants. Overall we antici-
pate an 80% response rate. Postal surveys will be done at
3, 12 and 24 months after randomisation. A baseline
questionnaire will be completed by all participants upon
recruitment to the trial. The greater frequency of data col-
lection in the first 12 months is necessary in order to cap-
ture data on expected changes in direct and social costs to
participants in the first 12 months. Experience also sug-
gests that data on consultation rates and prescribed med-
ication can be gathered most accurately and reliably from
medical records. Manual abstraction will be performed by
trained research nurses at the end of follow up for all par-
ticipants.
Adverse events will be recorded by self completion daily
diaries (parent or child) which will be collected four
weekly and GP records which will be examined at the end
of the 24 months follow up period. Expected adverse
events include infection, haemorrhage and pain following
tonsillectomy with possible hospital readmission as well
as sore throat, nausea, fever and dysphagia. All adverse
events will be managed as per normal care, since the inter-
vention process of this study does not deviate from nor-
mal care.
Data handling and record keeping
Only anonymised non-identifiable data will be recorded
by the site's research teams from personal medical
records. Health diaries and follow-up questionnaires will
be anonymous and returned to the trial centre in reply-
paid envelopes. For linking purposes these data sets willBMC Ear, Nose and Throat Disorders 2006, 6:13 http://www.biomedcentral.com/1472-6815/6/13
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have unique study identifiers. Only the lead researcher,
trial manager and trial administrator will have access to
the key which links study identifiers to individual data
sets. Personal details (participants full name and address)
will be stored on a secure database at CHSR for the pur-
pose of sending out questionnaires and diaries centrally.
All data held for analysis will be held in accordance with
the Data Protection Act. On completion of the study and
associated dissemination the Trial Master File will be
archived in the CHSR for 10 years. Trial sites will be
responsible for archiving their own documentation.
Economic evaluation
An economic evaluation will be carried out alongside the
clinical trial in order to ascertain the cost-effectiveness
from a societal perspective with a focus on health service
and families[35]. The cohort sample will not be included
in the economic evaluation except for the purpose of val-
idation and estimating the representativeness of cost and
benefit data for trial participants.
Measure of benefits used and study type
Cost consequences analysis (CCA), cost-effectiveness
analysis (CEA) and cost utility analysis (CUA) will be con-
ducted. In CCA, all the outcomes used in the clinical study
will be adopted as measures of benefits, including the
QoL dimensions. In CEA, the benefits will be measured by
the number of events of recurrent sore throat and the
number of symptom-free days. In CUA, different health
outcomes will be combined with QoL dimensions.
Resources data collected within the trial and costing methods
Medical resource data will relate to the interventions
under investigation, any use of health care services due to
'sore throat' episodes not averted, treatment of drug side-
effects, surgery complications and long term sequelae.
Services to be monitored include: outpatient visits and
hospitalisations, investigations, A&E admissions, visits
and telephone consultations to and from the GP and any
other health care professionals, use of medications
(including antibiotics, analgesics, and drugs to manage
antibiotic side-effects), and any other use of health care
services in both the private and public sectors. Manpower
data will be collected separately for each main category of
staff. Participants' out of pocket expenses such as over the
counter medicines will be reported. Costing of health care
resources will be undertaken in a parallel study and a
mixed approach using micro-costing and gross-costing
methods will be used[36]. We will cost resources using
health service pay and price data. Where appropriate,
these will be integrated using national published data [37-
39]. Where relevant, costs will be broken down into capi-
tal, staff, consumable and overhead costs. This will aid the
production of different cost scenarios. The impact of the
interventions on the time 'invested' by children and carers
because of illness, treatment and rehabilitation will also
be assessed. Children's days of restricted activity and their
level of functioning; time off school; carers' time off work;
children's and carers' time involved in outpatients attend-
ance (such as travel time, waiting time and the duration of
the clinical visit) and impact on children's and carers'
quality of life will be monitored. For carers' in paid/
unpaid work, time will be valued in monetary terms.
Costing will be undertaken using the human capital
approach and the friction cost method[40]. Those
resources for which we find a statistically significant dif-
ference between the groups will be costed. Those which
show no statistically significant difference but are of prac-
tical significance in their contribution to costs, will also be
costed. The cost analysis will not differ across the different
types of economic evaluations. However in the CUA,
when carers' preferences will be assessed, particular cau-
tion will be used to avoid double counting the loss of
income due to work absences[41]. Whenever applicable,
a discount rate of 6% will be used, which is the rate cur-
rently used by the public sector in the UK. Costs will be
expressed in UK pounds sterling. Costs will be expressed
in the prices of the year in which the final analysis will be
carried out and if necessary inflation method will be used
to update costs data.
Resources/costs data collected outwith the trial
The study is not powered to detect significant differences
for rare events. Given the relatively low incidence of surgi-
cal complications, long-term sequelae due to surgery and
drugs side-effects, data on the related use of resources,
costs to the carers and impact on children will be gathered
outwith the trial, from the literature and from experts'
opinions. Consensus estimates will be obtained by inter-
viewing a panel of experts, including members of the
study team and others. The source of the data will always
be explicitly stated.
Synthesis of costs and benefits
Depending on the outcome measure, if there is no statis-
tically significant evidence that one treatment strategy is
more effective than another, a cost-minimisation frame-
work will be used and the less expensive form of care will
be recommended. If one strategy appears to be dominant
(i.e. to be more effective and less costly than the alterna-
tive), the uptake will be recommended. If one form of care
appears to be more effective and more expensive than the
comparator, estimates of incremental cost-effectiveness
(and cost-utility) ratios will be generated. A judgement
will be required in a policy making context to establish
whether the additional benefits should be achieved sus-
taining the additional costs. In any case, recommenda-
tions will be made taking into account the generalisability
of the results.BMC Ear, Nose and Throat Disorders 2006, 6:13 http://www.biomedcentral.com/1472-6815/6/13
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Sensitivity analysis
To handle uncertainty not related to sampling variations
and to enhance the generalisability of the results, one-
way; multi-way and extreme scenario analysis will be
undertaken as appropriate and confidence intervals for
cost-effectiveness ratios will be estimated under different
scenarios[42]. A sensitivity analysis taking into account
differences in resource use which are practically signifi-
cant (i.e. potentially costly) but which have not been
shown to be statistically significant, will also be under-
taken. The sensitivity analysis will also make explicit all
the simplifying assumptions made to collect the data[43].
The application of discounting to the benefits will also be
tested in the sensitivity analysis, as well as a range of dis-
count rates. Particular attention will also be given to
whether the costs data used reflect the true marginal
opportunity costs of the resources used. When more than
one reliable source of information is available, such data
will be used as a term of comparison. The use of different
costing methods for multi-centre studies will be explored.
Earlier studies [28-31]. suggest that longer term outcomes
such as reduction in recurrent sore throat may show only
marginal benefits. An equivalence trial with a substan-
tially larger sample size would be necessary to capture sig-
nificant longer-term outcomes. To contain the cost of the
trial we have not proposed a three year follow up. How-
ever, the future sequence of clinical events and economic
impact will be modelled beyond 2-year follow-up. The
relevant data will be derived from studies which will be
available and experts' opinions.
Measuring participants' preferences and utilities
There is a need to value the effectiveness of interventions
taking account of the risk of surgery and its long-term
sequelae (e.g. sleep, eating, speech, disturbances, regres-
sive behaviour[44]). The utility assessments will also pro-
vide insight into informed choice models[45]. Older
children's and carers' values will be used to elicit prefer-
ences for trade-off between the perceived risks and bene-
fits of surgery versus drugs treatment. Preferences will
relate to temporary and chronic scenarios associated with
morbidity and QoL because of symptoms and treatment
complications. The scenarios will be developed selecting
the health outcomes and QoL domains relevant to the
problem. Interviews will be carried out with a sample of
older children and carers from the cohort group, and the




In this trial we anticipate a fairly large difference in the pri-
mary clinical outcome (the reported number of episodes
of sore throat in the two years after randomisation) with
an effect size of around 1.0, but a smaller difference in a
number of psycho-social outcomes including health-
related quality of life, with an effect size of 0.33. No stand-
ard sample size formula is available for economic evalua-
tions, and a number of methods have been proposed [47-
49]. The information which is currently available limit the
use of such methods in practical applications. Published
data[17] suggest that tonsillectomy may lead to a reduc-
tion of approximately 1.5 days per year in missed school-
ing. Given a reported standard deviation of 4.5, to detect
this difference with 80% power we would need approxi-
mately 142 children in each arm of the trial assuming a
significance level of 5%. A sample size of 142 children in
the cohort group will allow us to detect similar differences
between the cohort group and propositi. The sample will
be stratified by age (4–7, 8–11, 12–15). With a total of
284 children, we will have approximately 47 randomised
to each treatment arm in each strata. Given that the stand-
ard deviation of the number of sore throats per year is
2.0).)18, we will be able to estimate the difference
between treatments in each strata with a standard error of
0.41. (Equivalently we would have 90% power to detect a
difference of 1.35 episodes of sore throat per year in each
strata assuming a type 1 error of 0.05). It is anticipated
that the difference in outcome between the two arms of
the trial will be approximately 2 episodes in the second
year of follow up. A sample size of 142 children in each
arm should enable us to measure this difference with suf-
ficient precision to undertake a meaningful economic
analysis.
Main analysis
An intention to treat analysis will be performed. In partic-
ular, children randomised to non-surgical conventional
medical treatment will be retained in that group for the
analysis even if they subsequently receive a tonsillectomy.
The primary clinical outcome measure will be the number
of episodes of sore throat. This variable will be analysed
using generalised linear modelling assuming a Poisson
error structure with a log link function[50]. By fitting the
difference between the two experimental groups as a fixed
effect, interval estimates of the effect of tonsillectomy (in
each of the first two years of follow up) will be generated.
These estimates will then be used in the economic analy-
sis. The same approach will be used to analyse the other
outcomes. A Poisson error structure will be assumed for
data in the form or a count (such as the number of epi-
sodes of absence from school) and normal error structure
adopted for continuous variables (such as the quality of
life indices).
Secondary analysis
The aim of secondary analysis is to determine whether we
can identify groups of children who benefit from surgical
treatment. It is hypothesised that disease severity may be
an important factor. A severity index based on history ofBMC Ear, Nose and Throat Disorders 2006, 6:13 http://www.biomedcentral.com/1472-6815/6/13
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the condition during the year before entry to the study will
be derived using data recorded in GP records. The rela-
tionship between severity and the effect of tonsillectomy
will then be investigated using the modelling approach
described above.
Economic analysis
We expect skewness in the distribution of use of
resources/costs[51]. In the presence of skewness, the loga-
rithmic transformation of data is not recommended, and
the application of non-parametric tests can provide mis-
leading results (economic studies aim to base the analysis
on arithmetic means and not median values) [52,53]. The
non-parametric bootstrap test can be the most appropri-
ate[53], since it does not require any assumptions about
the normality of data and equality of the variance or shape
of the distributions. The t-test can be safely used if the
sample size is not too small[52]. Depending on the level
of skewness of data obtained we will make a judgement
on which of these two methods can be safely applied. The
mean costs estimates and (incremental) cost-effectiveness
ratios, and conventional measures of variances will be
reported[42].
Cohort analysis
The cohort of patients who decline to be randomised will
be used to assess the external validity of the main study.
Baseline characteristics of the cohort will be compared
with those of the study population using standard tests for
the comparison of two independent samples (e.g. the t-
test or Mann-Whitney test as appropriate). Outcome for
the cohort will be compared with outcome for the two
groups of study participants using the modelling
approach described above.
Trial steering committee
The study has a Trial Steering Committee which meets 6
monthly. The Trial Steering Committee is responsible for
monitoring public interest and ensuring issues relating to
research governance are met. The trial does not have a
data monitoring committee since it examines routine
therapies.
Consumer involvement
Consumer involvement will be encouraged and facilitated
throughout the study by the establishment of a consumer
advisory panel. We will use the advisory panel to help
clarify important outcomes for children and their parents
(or carers) and to assist in the development of participant-
oriented data-collection methods. By consumer we
include here children and their parents as well as repre-
sentatives of appropriate advocacy groups such as the
Patients Association. Our experience of consumer panels
in the development and implementation of other studies
(e.g. quality of life of people with dementia and treatment
for primary biliary cirrhosis of the liver) have highlighted
the different types of involvement and the different ways
that consumers can be involved in primary research. Par-
ents and children will be involved in an advisory capacity
rather than in a full participatory role. We will establish
and convene regularly the consumer advisory panel in
which the group process will use focus group methods.
Throughout the project (at least annually) we will use the
advisory panel to voice participants' concerns and to iden-
tify participant-oriented solutions to such concerns.
Ethical approval
The conduct of this study will be in accordance with the
ethical principles set out in the Declaration of Helsinki.
The trial has approval from MREC and all the associated
LRECs. The trial also holds a Clinical Trial Authorisation
from the MHRA. The trial has NHS R&D and Caldicott
Guardian approval from each participating site. There are
no particular ethical problems with this trial. The ethical
challenge is as with any surgical randomised trial where
one arm is an irreversible procedure under general anaes-
thesia and the other limb effectively maintenance of the
status quo with reverting to surgery an outstanding
choice. Set against the surgical risk, however, is the essen-
tially curative nature of the intervention – no tonsillitis
can occur once the tonsils have been removed. Further,
the children under consideration all have qualifying levels
of sore throat and would otherwise be eligible for surgery.
In other words the issue is more the withholding of ton-
sillectomy rather than one of random allocation to inter-
vention. All subjects will provide written informed
consent before any study procedures are carried out and a
participant information sheet will be provided. As part of
the consent process participants must agree to researchers
& regulatory representatives having access to their medical
records. Participants will also be informed that they have
the right to withdraw from the study at any time.
The NHS Trust has liability for clinical negligence that
harms individuals toward whom they have a duty of care.
NHS Indemnity covers NHS staff and medical academic
staff with honorary contracts conducting the trial.
Discussion
As with all pragmatic randomised controlled trials it is
impossible to control the external environment in which
the research is taking place. Since this trial began a
number of factors have arisen which could affect the out-
come. Firstly there appears to be a reduction in the inci-
dence of respiratory tract infections or at least a reduction
in the number of patients presenting to primary health
care with respiratory tract infections[54]. This will inevita-
bly lead to a reduction in the number of children being
referred to secondary care for recurrent throat infections.
Secondly it has come to light that there are marked socio-BMC Ear, Nose and Throat Disorders 2006, 6:13 http://www.biomedcentral.com/1472-6815/6/13
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economic differences in consultation rates in primary
health care which are not reflected in operation rates for
tonsillitis in secondary care[55]. Lower socio-economic
groups use NHS services for tonsillitis less in relation to
need than higher socio-economic groups. Again this has
implications for the rate of referral to secondary care. The
results from the recent National Prospective Tonsillec-
tomy Audit[56] may also have led to an alteration in the
surgical techniques favoured by our trial consultants how-
ever surgical methods and any associated post operative
complications are recorded for the trial. In addition there
is anecdotal evidence that the Government's waiting list
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